| Bioactivity | SARS-CoV-2-IN-22 is a SARS-CoV-2 pseudovirus entry inhibitor with an IC50 value of 16.96 µM[1]. |
| Target | IC50: 16.96 µM (SARS-CoV-2) |
| Invitro | SARS-CoV-2-IN-22 (Compound 9a) effectively blocks the binding of SARS-CoV-2 to the host ACE2 receptor through dual recognition of SARS-CoV-2 spike receptor-binding domain (RBD) and human ACE2. SARS-CoV-2-IN-2 displays no cytotoxicity to normal cells (LO2)[1]. |
| Name | SARS-CoV-2-IN-22 |
| CAS | 2710278-53-6 |
| Formula | C27H24N2O3S |
| Molar Mass | 456.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ting Xu, et al. Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors. Bioorg Med Chem. 2022 Aug 1;67:116838. |